Executive Brief

News Report

The News: FDA approves Immgolis as the first interchangeable biosimilar to Simponi for RA and UC.
Clinical Win: This approval enhances treatment options for patients with chronic autoimmune conditions.
Target Specialty: Rheumatology

Key Data at a Glance

Approval Date: May 15, 2026
Indications: Moderately to severely active RA and UC

The FDA has approved Immgolis (golimumab-sldi) as the first interchangeable biosimilar to Simponi (golimumab) for the treatment of rheumatoid arthritis (RA) and ulcerative colitis (UC). This approval, announced on May 15, 2026, is significant for healthcare providers as it expands treatment options for patients with these chronic autoimmune conditions.

Clinical Context

Rheumatoid arthritis (RA) is a chronic inflammatory disorder that primarily affects joints but can also impact other systems in the body, leading to significant morbidity and decreased quality of life. Ulcerative colitis (UC) is a form of inflammatory bowel disease that causes inflammation and ulcers in the lining of the colon, resulting in various gastrointestinal symptoms. Current standard treatments for RA and UC include tumor necrosis factor (TNF) inhibitors like golimumab, which help reduce inflammation by blocking TNFα. However, access to these medications can be limited due to high costs. The introduction of biosimilars, such as Immgolis, is expected to provide a more affordable alternative while maintaining similar efficacy and safety profiles. The FDA's designation of Immgolis as an interchangeable biosimilar allows pharmacists to substitute it for the reference product without consulting the prescriber, which could streamline treatment processes and improve patient access.

Key Findings

The FDA approved Immgolis as an interchangeable biosimilar to Simponi for the treatment of moderately to severely active rheumatoid arthritis and ulcerative colitis in adults [1].
Immgolis is administered via subcutaneous injection in a single-dose prefilled syringe, while Immgolis Intri, also approved, is given as an intravenous infusion [1].
The approval was based on a comprehensive review demonstrating that Immgolis is highly similar to the reference product, with no clinically meaningful differences in safety or efficacy [1].

Safety & Tolerability

Common side effects reported for Immgolis include upper respiratory tract infections, nasopharyngitis, and injection site reactions, similar to those observed with Simponi [9].

What This Means for Clinical Practice

The approval of Immgolis as an interchangeable biosimilar presents a new opportunity for clinicians treating patients with rheumatoid arthritis and ulcerative colitis. With the ability to substitute Immgolis for Simponi without prior consultation, pharmacists can enhance medication accessibility and potentially reduce costs for patients. Clinicians should be aware of state-specific regulations regarding biosimilar substitutions and ensure patients are informed about their treatment options. The introduction of Immgolis may also encourage discussions about treatment adherence and monitoring for side effects, as patients transition between products. Ultimately, this development could lead to improved management of RA and UC, enhancing patient outcomes and quality of life while addressing economic barriers to treatment.

Clinical Perspective

Workflow: Clinicians should familiarize themselves with state regulations regarding biosimilar substitutions to facilitate patient access.

Economics: The introduction of Immgolis is expected to lower treatment costs, improving affordability for patients.

Patient Outcomes: Enhanced access to effective treatments may lead to better management of RA and UC, improving overall patient quality of life.

Dr. Deepak Nair, Rheumatology

FDA Approves Immgolis as First Interchangeable Golimumab Biosimilar for RA and UC

Executive Brief

Key Data at a Glance

Clinical Context

Key Findings

Safety & Tolerability

What This Means for Clinical Practice

Clinical Perspective

References

Get weekly drug updates for Rheumatology in your inbox.

Related Drug Updates

FDA Approves Anifrolumab for Subcutaneous Home Administration in SLE

FDA Approves First Interchangeable Biosimilars for Rheumatoid Arthritis: Cost Savings and Formulary Implications

FDA Approves Deucravacitinib for Psoriatic Arthritis: 54% Joint Swelling Reduction

Verified HCP Portal